We narrowed to 126 results for: PLE

#137128-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Coff/Fon-sRGECO (#137128). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Coff/Fon-sRGECO plasmid DNA. EF1a-driven, Flp-dependent expression of cytosolic sRGECO calcium sensor (inhibited in presence of Cre). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

June 22, 2021

Academic Institutions and Nonprofits only

#137131-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Coff/Fon-BFP (#137131). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Coff/Fon-BFP plasmid DNA. EF1a-driven, Flp-dependent expression of BFP (inhibited in presence of Cre). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 5, 2021

Academic Institutions and Nonprofits only

#92379-LV

Ready-to-use Lentiviral Prep particles produced from Human CRISPRa sgRNA library Calabrese in backbone XPR_502 (P65 HSF), Set A (#92379). In addition to the viral particles, you will also receive purified Human CRISPRa sgRNA library Calabrese in backbone XPR_502 (P65 HSF), Set A plasmid DNA. Ready-to-use lentiviral pooled library for CRISPR activation screening in human cells. Contains 56,762 sgRNAs, targeting 18,885 genes. Concentrated lentiviral particles carrying set A of the Calabrese human CRISPRa sgRNA activation library in backbone XPR_502 (P65 HSF) .

John Doench, David Root

Sanson et al Nat Commun. 2018 Dec 21;9(1):5416. doi:

Aug. 3, 2017

Academic Institutions and Nonprofits only

#137136-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Fon-oScarlet (#137136). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Fon-oScarlet plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of oScarlet. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 5, 2021

Academic Institutions and Nonprofits only

#137139-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon-ChR2(ET/TC)-EYFP (#137139). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon-ChR2(ET/TC)-EYFP plasmid DNA. nEF-driven, Cre and Flp-dependent expression of ChR2(E123T/T159C)-EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 19, 2021

Academic Institutions and Nonprofits only

#137138-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Coff/Fon-oScarlet (#137138). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Coff/Fon-oScarlet plasmid DNA. EF1a-driven, Flp-dependent expression of oScarlet (inhibited in presence of Cre). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 8, 2021

Academic Institutions and Nonprofits only

#137121-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Coff/Fon-GCaMP6M (#137121). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Coff/Fon-GCaMP6M plasmid DNA. EF1a-driven expression of GCaMP6m in the presence of Flp recombinase (inhibited in the presence of Cre recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 23, 2020

Academic Institutions and Nonprofits only

#137127-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-sRGECO (#137127). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-sRGECO plasmid DNA. EF1a-driven, Cre-dependent expression of cytosolic sRGECO calcium sensor (inhibited in presence of Flp). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 18, 2021

Academic Institutions and Nonprofits only

#137124-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Coff/Fon-GCaMP6F (#137124). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Coff/Fon-GCaMP6F plasmid DNA. EF1a-driven, Flp-dependent expression of GCaMP6f (inhibited in presence of Cre). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 18, 2021

Academic Institutions and Nonprofits only

#137133-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-mCherry (#137133). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-mCherry plasmid DNA. EF1a-driven, Cre-dependent expression of mCherry (inhibited in presence of Flp). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 5, 2021

Academic Institutions and Nonprofits only

#55641-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Oct. 21, 2024

Academic Institutions and Nonprofits only

#137126-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Fon-sRGECO (#137126). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Fon-sRGECO plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of cytosolic sRGECO calcium sensor. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 5, 2021

Academic Institutions and Nonprofits only

#137123-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-GCaMP6F (#137123). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-GCaMP6F plasmid DNA. EF1a-driven, Cre-dependent expression of GCaMP6f (inhibited in presence of Flp). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 5, 2021

Academic Institutions and Nonprofits only

#137157-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Coff/Fon-iC++-EYFP (#137157). In addition to the viral particles, you will also receive purified pAAV-nEF-Coff/Fon-iC++-EYFP plasmid DNA. nEF-driven, Flp-dependent expression of chloride-conducting channelrhodopsin iC++-EYFP (inhibited in presence of Cre) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Feb. 23, 2021

Academic Institutions and Nonprofits only

#137156-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-iC++-EYFP (#137156). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-iC++-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of chloride-conducting channelrhodopsin iC++-EYFP (inhibited in presence of Flp) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 25, 2020

Academic Institutions and Nonprofits only

#137129-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Fon-BFP (#137129). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Fon-BFP plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of BFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 8, 2021

Academic Institutions and Nonprofits only

#137164-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon/Von eYFP (#137164). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon/Von eYFP plasmid DNA. nEF-driven, Cre, Flp and VCre-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 12, 2020

Academic Institutions and Nonprofits only

#128485-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-iSeroSnFR-Nlgn (#128485). In addition to the viral particles, you will also receive purified pAAV-CAG-iSeroSnFR-Nlgn plasmid DNA. CAG-driven expression of a fluorescent reporter for serotonin (localized to dendrites). These AAV preparations are suitable purity for injection into animals.

Lin Tian

Unger et al Cell. 2020 Dec 12. pii: S0092-8674(20)31

Feb. 27, 2024

Academic Institutions and Nonprofits only

#128486-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-FLEx-iSeroSnFR (#128486). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEx-iSeroSnFR plasmid DNA. CAG driven, Cre-dependent expression of iSeroSnFR. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Unger et al Cell. 2020 Dec 12. pii: S0092-8674(20)31

Sept. 27, 2024

Academic Institutions and Nonprofits only

#137163-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2-EYFP (#137163). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of ChR2-EYFP for optogenetic activation (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 23, 2020

Academic Institutions and Nonprofits only